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Background
The risk of breast cancer in postmenopausal women is
increased two-fold with obesity, and the majority of breast
tumours that arise are oestrogen-dependent. After meno-
pause, when the ovaries cease to produce oestrogens, it is
the local production of oestrogens within the breast adi-
pose stromal cells (ASCs) which promotes and sustains
tumour growth. This is largely due to the increased
expression of aromatase, responsible for the conversion of
androgens to oestrogens. Aromatase expression in breast
cancer is known to be under the control of a proximal
promoter, promoter PII, which is maximally activated by
cAMP-dependent mechanisms. We have previously
demonstrated that the LKB1/AMPK pathway is a key
negative regulator of aromatase expression within the
breast by inhibiting the nuclear translocation of the CREB
co-activator CRTC2 [1]. We have also demonstrated that
the tumour-derived factor prostaglandin E2 (PGE2) and
the obesity-associated factor leptin stimulate aromatase
expression by inhibiting LKB1 and AMPK expression and
activity. Hypoxia inducible factor-1a (HIF1a) is emerging
as a potent regulator of glycolysis in tumour cells and we
have identified a putative hypoxia response element in aro-
matase promoter Pll immediately adjacent the cAMP
response element, known to be bound by the CREB-
CRTC2 complex in ASCs in breast cancer. We therefore
hypothesise that HIF1a may be involved in regulating aro-
matase in breast cancer.
Materials and methods
Primary human breast ASCs were isolated from tissue
after breast reduction surgery. Real-time PCR, Western
blotting, immunofluorescence and high content screening
were used to assess HIF1a expression and localisation
after PGE2 treatment. Chromatin immunoprecipitation
(ChIP) was performed to examine the interaction of
HIF1a with aromatase promoter PII and reporter assays
were performed to assess the effect of HIF1a on PII activ-
ity. Double immunohistochemistry for HIF1a and aroma-
tase was also performed on sections of formalin-fixed
paraffin-embedded breast tissue from breast cancer
patients and cancer-free patients.
Results
We have found that PGE2 increases HIF1a transcript
expression, nuclear localisation and binding to aromatase
PII in primary human breast ASCs. Moreover, HIF1a
causes a significant increase in PII activity and acts coop-
eratively with CREB to cause this induction. Data from
breast cancer patient samples demonstrates that HIF1a is
also increased in tumour-associated ASCs compared to
breast tissue from cancer-free women. Interestingly, the
majority of ASCs from breast cancer patient samples dis-
play staining for both HIF1a and aromatase.
Conclusions
This study is part of a growing body of evidence indicating
that dysregulated metabolism is not only a characteristic
of adipocytes in obesity and epithelial cells in cancer, but
also occurs in tumour-associated ASCs. We demonstrate
that dysregulation of metabolic pathways is accompanied
by an increase in aromatase expression within the breast
adipose and provide an additional mechanism whereby
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obesity is linked to breast cancer. Clinical studies are cur-
rently underway to explore the use of drugs which target
these pathways, such as metformin, for their use as novel
aromatase inhibitors for the prevention and treatment of
postmenopausal breast cancer.
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